CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg +1 morecombination
Likely dose
Budesonide/albuterol sulfate metered-dose inhaler 160/180 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04234464
NCT04234464Phase 3Completed

A Randomized, Double-blind, Single-dose, 2-Period, Crossover Study to Assess the Efficacy of PT027 Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult and Adolescent Subjects With Asthma

Bond Avillion 2 Development LP·interventional·Posted Jan 21, 2020·Updated Jan 13, 2022

In Brief

A Phase 3 clinical trial evaluating Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg and Placebo metered-dose inhaler for Exercise Induced Bronchospasm. Completed, enrolled 60 participants across 6 sites.

Detailed Summary

This is a multicenter, randomized, double-blind, single-dose, placebo-controlled, 2-period, crossover study to evaluate the efficacy and safety of budesonide/albuterol metered-dose inhaler (BDA MDI/PT027) as compared with a placebo metered-dose inhaler (placebo MDI) on exercise-induced bronchoconstriction (EIB) in adult and adolescent subjects with asthma. Subjects will receive each study treatment on separate visits and undergo a treadmill exercise challenge test for up to 10 minutes so that the effect of study treatment on exercise-induced bronchoconstriction can be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 21, 2020
Enrollment StartJan 15, 2020
Primary CompletionAug 28, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.4 years ago

Interventions

Budesonide/albuterol sulfate metered-dose inhaler 160/180 μgcombination

Budesonide/albuterol sulfate combination inhalation aerosol single dose

Placebo metered-dose inhalercombination

Placebo inhalation aerosol single dose